Arrowhead Research | ARWR - Ordinary Share Capital


Arrowhead Research reported $140.57M in Ordinary Share Capital for its fiscal quarter ending in March of 2026.





Ordinary Share Capital Change Date
Agios Pharmaceuticals USD 59.34M 892K Mar/2026
Alnylam Pharmaceuticals USD 133.73M 290K Jun/2026
Anika Therapeutics USD 13.89M 532K Dec/2025
Arrowhead Research USD 140.57M 3.18M Mar/2026
Heron Therapeutics USD 188.31M 4.99M Dec/2025
Incyte USD 200.98M 1.03M Jun/2026
Ionis Pharmaceuticals USD 165.64M 265K Jun/2026
Ligand Pharmaceuticals USD 19.66M 19.64M Sep/2025
Merck USD 2.47B 4.93M Mar/2026
Moderna USD 391M 2M Sep/2025
Nektar Therapeutics USD 29.47M 9.09M Mar/2026
Novartis USD 1.9B 7.38M Jun/2026
Sarepta Therapeutics USD 105.57M 607K Mar/2026
TG Therapeutics USD 155.31M 95K Dec/2025
Ultragenyx Pharmaceutical USD 98.3M 1.7M Mar/2026
Vertex Pharmaceuticals USD 253.3M 900K Jun/2026
Xencor USD 74.06M 2.19M Mar/2026